Literature DB >> 8394464

Structural and functional characterization of rev-like transcripts of equine infectious anemia virus.

R Rosin-Arbesfeld1, M Rivlin, S Noiman, P Mashiah, A Yaniv, T Miki, S R Tronick, A Gazit.   

Abstract

Three cDNA clones representing structurally distinct transcripts were isolated from a cDNA library prepared from cells infected with equine infectious anemia virus (EIAV) by using a probe representing the S3 open reading frame, which is thought to encode Rev. One species, designated p2/2, contained four exons and was identical to a previously described polycistronic mRNA that encodes Tat. This transcript was predicted to also direct the synthesis of a truncated form of the transmembrane protein and a putative Rev protein whose N-terminal 29 amino acids, derived from env, are linked to S3 sequences. The second cDNA, p176, also consisted of four exons which were generated by two of three of the same splicing events that occur with p2/2 but not with the Tat mRNA. The alternative splice site giving rise to the second exon of p176 results in a bicistronic message that would encode the same transmembrane and Rev proteins as p2/2. The first exon of the third transcript, p20, was identical to those of p2/2 and p176 but was spliced directly to S3. This monocistronic message could encode a second form of Rev that lacks env sequences, provided that Rev synthesis would initiate at a non-AUG codon. The coding capacity of each cDNA was assessed in a eukaryotic system using S3 antisera. Two putative Rev proteins with apparent molecular masses of 18 and 16 kDa were expressed by p2/2 and p176, while p20 expressed only a 16-kDa species. Analysis of EIAV-infected cells with S3 antisera revealed the presence of an 18-kDa protein. Surprisingly, the same protein was detected in purified virions. By using a reporter construct, the chloramphenicol acetyltransferase gene linked to EIAV env sequences, we were able to demonstrate greatly enhanced chloramphenicol acetyltransferase activity in cells cotransfected with this construct and any of the three cDNAs.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8394464      PMCID: PMC237968     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  51 in total

1.  Localization of sequences responsible for trans-activation of the equine infectious anemia virus long terminal repeat.

Authors:  L Sherman; A Gazit; A Yaniv; T Kawakami; J E Dahlberg; S R Tronick
Journal:  J Virol       Date:  1988-01       Impact factor: 5.103

2.  Specific regulation of mRNA splicing in vitro by a peptide from HIV-1 Rev.

Authors:  J Kjems; A D Frankel; P A Sharp
Journal:  Cell       Date:  1991-10-04       Impact factor: 41.582

3.  Characterization of a cDNA clone encoding the visna virus transactivating protein.

Authors:  J L Davis; J E Clements
Journal:  Proc Natl Acad Sci U S A       Date:  1989-01       Impact factor: 11.205

4.  Genetic structure and function of an early transcript of visna virus.

Authors:  V Mazarin; I Gourdou; G Quérat; N Sauze; R Vigne
Journal:  J Virol       Date:  1988-12       Impact factor: 5.103

5.  Effects of intercistronic length on the efficiency of reinitiation by eucaryotic ribosomes.

Authors:  M Kozak
Journal:  Mol Cell Biol       Date:  1987-10       Impact factor: 4.272

6.  Isolation and characterization of the c-fos(rat) cDNA and analysis of post-translational modification in vitro.

Authors:  T Curran; M B Gordon; K L Rubino; L C Sambucetti
Journal:  Oncogene       Date:  1987       Impact factor: 9.867

7.  Nucleotide sequence analysis of equine infectious anemia virus proviral DNA.

Authors:  T Kawakami; L Sherman; J Dahlberg; A Gazit; A Yaniv; S R Tronick; S A Aaronson
Journal:  Virology       Date:  1987-06       Impact factor: 3.616

8.  Genome organization and transactivation of the human immunodeficiency virus type 2.

Authors:  M Guyader; M Emerman; P Sonigo; F Clavel; L Montagnier; M Alizon
Journal:  Nature       Date:  1987 Apr 16-22       Impact factor: 49.962

9.  Analysis of multiple mRNAs from pathogenic equine infectious anemia virus (EIAV) in an acutely infected horse reveals a novel protein, Ttm, derived from the carboxy terminus of the EIAV transmembrane protein.

Authors:  C E Beisel; J F Edwards; L L Dunn; N R Rice
Journal:  J Virol       Date:  1993-02       Impact factor: 5.103

10.  Sequence of simian immunodeficiency virus from macaque and its relationship to other human and simian retroviruses.

Authors:  L Chakrabarti; M Guyader; M Alizon; M D Daniel; R C Desrosiers; P Tiollais; P Sonigo
Journal:  Nature       Date:  1987 Aug 6-12       Impact factor: 49.962

View more
  6 in total

1.  CRM1-dependent function of a cis-acting RNA export element.

Authors:  Ileana Popa; Matthew E Harris; John E Donello; Thomas J Hope
Journal:  Mol Cell Biol       Date:  2002-04       Impact factor: 4.272

2.  Two species of Rev proteins, with distinct N termini, are expressed by caprine arthritis encephalitis virus.

Authors:  A Gazit; P Mashiah; H Kalinski; A Gast; R Rosin-Abersfeld; S R Tronick; A Yaniv
Journal:  J Virol       Date:  1996-04       Impact factor: 5.103

3.  Inhibitory activity of the equine infectious anemia virus major 5' splice site in the absence of Rev.

Authors:  W Tan; M Schalling; C Zhao; M Luukkonen; M Nilsson; E M Fenyö; G N Pavlakis; S Schwartz
Journal:  J Virol       Date:  1996-06       Impact factor: 5.103

4.  Demonstration that orf2 encodes the feline immunodeficiency virus transactivating (Tat) protein and characterization of a unique gene product with partial rev activity.

Authors:  A de Parseval; J H Elder
Journal:  J Virol       Date:  1999-01       Impact factor: 5.103

5.  Equine infectious anemia virus trans-regulatory protein Rev controls viral mRNA stability, accumulation, and alternative splicing.

Authors:  L Martarano; R Stephens; N Rice; D Derse
Journal:  J Virol       Date:  1994-05       Impact factor: 5.103

6.  Development and characterization of an in vivo pathogenic molecular clone of equine infectious anemia virus.

Authors:  R F Cook; C Leroux; S J Cook; S L Berger; D L Lichtenstein; N N Ghabrial; R C Montelaro; C J Issel
Journal:  J Virol       Date:  1998-02       Impact factor: 5.103

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.